Publications by authors named "Mirna Reihl-Crnogaj"
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease that is manifested by the sensation of dry eyes and dry mouth. The higher incidence of non-Hodgkin lymphoma (NHL) among pSS has already been extensively researched. However, there are uncertanties whether the mortality risk in pSS patients and in pSS patients with NHL is increased.
View Article and Find Full Text PDFArticle Synopsis
- TNF-α inhibitors, like adalimumab, have become essential for treating psoriatic arthritis, but they can have unwanted side effects in some patients.
- A patient with psoriasis, psoriatic arthritis, and uveitis developed symptoms of multiple sclerosis after 4 months of adalimumab treatment, despite having no prior neurological issues.
- The case raises questions about whether the drug induced demyelination or simply revealed an underlying condition, highlighting the importance of monitoring side effects in clinical practice.
Article Synopsis
- - Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) remain essential for treating rheumatoid arthritis (RA), even with the availability of targeted therapies.
- - Methotrexate is widely considered the most effective treatment option, often used alone or with other drugs, while alternatives like leflunomide and sulfasalazine are also valid, and (hydroxy)chloroquine is typically used in combination.
- - The review aims to give a practical understanding of the pharmacology and treatment guidelines for each csDMARD, highlighting the benefits of combining different csDMARDs, especially in resource-limited settings.
Adult-onset Still's disease (AOSD) is defined as a systemic inflammatory disorder of unknown aetiology and is classified as a multigene autoinflammatory disease. Treatment of AOSD still remains mostly empirical with nonsteroidal anti-inflammatory drugs, glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs or cyclosporin A. Inhibitors of tumour necrosis factor-alpha and interleukin-1 (IL-1) antagonists have shown efficacy in certain subsets of patients with AOSD.
View Article and Find Full Text PDF